Manuel Melo Pires

Manuel Melo Pires

Auto-generated profile, based on publicly available information

Manuel Melo Pires

Neuropathology Unit, Centro Hospitalar do Porto, Porto, Portugal

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2012 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
VMVera Miranda-Gonçalves
Vera Miranda-Gonçalves
MHMrinalini Honavar
Mrinalini Honavar
CPCéline Pinheiro
Céline Pinheiro
Olga MartinhoOlga Martinho
Olga Martinho
MPManuel M Pires
Manuel M Pires
FBFatima Baltazar
Fatima Baltazar
Background Gliomas exhibit high glycolytic rates, and monocarboxylate transporters (MCTs) play a major role in the maintenance of the glycolytic metabolism through the proton-linked transmembrane transport of lactate. However, their role in gliomas is poorly studied. Thus, we aimed to characterize the expression of MCT1, MCT4, and their chaperone CD147 and to assess the therapeutic impact of MCT inhibition in gliomas. Methods MCTs and CD147 expressions were characterized by immunohistochemistry in nonneoplastic brain and glioma samples. The effect of CHC (MCT inhibitor) and MCT1 silencing was assessed in in vitro and in vivo glioblastoma models. Results MCT1, MCT4, and CD147 were overexpressed in the plasma membrane of glioblastomas, compared with diffuse astrocytomas and nonneoplastic brain. CHC decreased glycolytic metabolism, migration, and invasion and induced cell death in U251 cells (more glycolytic) but only affected proliferation in SW1088 (more oxidative). The effectiveness of CHC in glioma cells appears to be dependent on MCT membrane expression. MCT1 downregulation showed similar effects on different glioma cells, supporting CHC as an MCT1 inhibitor. There was a synergistic effect when combining CHC with temozolomide treatment in U251 cells. In the CAM in vivo model, CHC decreased the size of tumors and the number of blood vessels formed. Conclusions This is the most comprehensive study reporting the expression of MCTs and CD147 in gliomas. The MCT1 inhibitor CHC exhibited anti-tumoral and anti-angiogenic activity in gliomas and, of importance, enhanced the effect of temozolomide. Thus, our results suggest that development of therapeutic approaches targeting MCT1 may be a promising strategy in glioblastoma treatment.

4 August 2014 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Closed access
PDF file
LMLuis Maia
Luis Maia
RMRui Magalhães
Rui Magalhães
JFJoel Freitas
Joel Freitas
RTRicardo Taipa
Ricardo Taipa
MPManuel Melo Pires
Manuel Melo Pires
TCTeresa Coelho
Teresa Coelho
Objectives Since liver transplant (LT) was introduced to treat patients with familial amyloid polyneuropathy carrying the V30M mutation (ATTR-V30M), ocular and cardiac complications have developed. Long-term central nervous system (CNS) involvement was not investigated. Our goals were to: (1) identify and characterise focal neurological episodes (FNEs) due to CNS dysfunction in ATTR-V30M patients; (2) characterise neuropathological features and temporal profile of CNS transthyretin amyloidosis. Methods We monitored the presence and type of FNEs in 87 consecutive ATTR-V30M and 35 non-ATTR LT patients. FNEs were investigated with CT scan, EEG and extensive neurovascular workup. MRI studies were not performed because all patients had cardiac pacemakers as part of the LT protocol. We characterised transthyretin amyloid deposition in the brains of seven ATTR-V30M patients, dead 3–13 years after polyneuropathy onset. Results FNEs occurred in 31% (27/87) of ATTR-V30M and in 5.7% (2/35) of the non-ATTR transplanted patients (OR=7.0, 95% CI 1.5 to 33.5). FNEs occurred on average 14.6 years after disease onset (95% CI 13.3 to 16.0) in ATTR-V30M patients, which is beyond the life expectancy of non-transplanted ATTR-V30M patients (10.9, 95% CI 10.5 to 11.3). ATTR-V30M patients with FNEs had longer disease duration (OR=1.24; 95% CI 1.07 to 1.43), renal dysfunction (OR=4.65; 95% CI 1.20 to 18.05) and were men (OR=3.57; 95% CI 1.02 to 12.30). CNS transthyretin amyloidosis was already present 3 years after polyneuropathy onset and progressed from the meninges and its vessels towards meningocortical vessels and the superficial brain parenchyma, as disease duration increased. Conclusions Our findings indicate that CNS clinical involvement occurs in ATTR-V30M patients regardless of LT. Longer disease duration after LT can provide the necessary time for transthyretin amyloidosis to progress until it becomes clinically relevant. Highly sensitive imaging methods are needed to identify and monitor brain ATTR. Disease modifying therapies should consider brain TTR as a target.

16 April 2016 in Brain
Verified
Journal Article
Open access
RTRicardo Taipa
Ricardo Taipa
CPConceição Pereira
Conceição Pereira
IRInês Reis
Inês Reis
IAIsabel Alonso
Isabel Alonso
ABAntónio Bastos-Lima
António Bastos-Lima
MMMarina Magalhães
Marina Magalhães
Mutations in DJ-1 (encoded by PARK7) are a very rare cause of early-onset recessive Parkinson’s disease. We describe a patient with early-onset parkinsonism, starting at the age of 22, with poor response to levodopa and additional features in progression (dystonia, pyramidal signs and dementia), who died when he was 49 years old. The neuropathological study showed severe substantia nigra and locus coeruleus neuronal loss, with diffuse Lewy body pathology (Lewy bodies, aberrant neurites, grain-like structures, spheroids and scattered glial pathology). Genetic analysis revealed a novel c.515T > A; p.L172Q mutation in the PARK7 gene. To evaluate the pathogenicity of this new mutation we explored DJ-1 expression levels in vitro showing a massive reduction in DJ-1 protein levels due to a highly unstable and rapidly degraded L172Q mutant. DJ-1 immunohistochemistry of brain tissue revealed no staining in our case. This is the first neuropathological report of a brain from DJ-1-linked parkinsonism that, although based on a single case study, suggests that DJ-1 mutations are causative of α-synucleinopathy. These results can help in the understanding of Parkinson’s disease pathophysiology, promote research studies to increase the knowledge on the pathways involved in the neurodegeneration process, and pave the way for new therapeutic interventions.

1 January 1994 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
JRJ. O. Rinne
J. O. Rinne
SDS. E. Daniel
S. E. Daniel
FSF. Scaravilli
F. Scaravilli
MPM. Pires
M. Pires
AHA. E. Harding
A. E. Harding
CMC. D. Marsden
C. D. Marsden

27 November 2017 in Neuropathology and Applied Neurobiology
Verified
Journal Article
Closed access
PDF file
RTRicardo Taipa
Ricardo Taipa
VFVítor Ferreira
Vítor Ferreira
PBP. Brochado
P. Brochado
ARAndrew Robinson
Andrew Robinson
IRI. Reis
I. Reis
NSNuno Sousa
Nuno Sousa

1 January 1994 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
PTP D Thompson
P D Thompson
KBK P Bhatia
K P Bhatia
PBP Brown
P Brown
MDM B Davis
M B Davis
MPM Pires
M Pires
CMC D Marsden
C D Marsden